Table 1– Clinical and laboratory data of investigated sarcoidosis patients
CharacteristicsSarcoidosisCXR stage ICXR stage IICXR stage IIICXR stage IV
Subjects62173384
Age yrs48±12 (28–77)45±13 (28–71)47±11 (29–70)52±9 (32–63)59±14 (44–77)
Males/females26/369/814/193/50/4
Smoking yes/no/ex6/43/133/11/33/21/90/7/10/4/0
CXR stages I/II/III/IV17/33/8/4173384
LS yes/no11/517/104/290/80/4
BAL fluid differential count
 Macrophages %74.5±13.0 (40.0–97.1)75.1±12.4 (49.4–91.1)75.2±12.6 (40.0–97.1)73.3±17.6 (44.4–92.1)68.9±13.4 (56.0–82.7)
 Lymphocytes %22.8±12.3 (2.0–54.0)24.0±12.1 (8.0–49.0)21.7±11.7 (2.0–47.0)24.6±17.9 (7.6–54.0)22.7±5.7 (16.7–28.0)
 Neutrophils %2.0±3.6 (0.0–18.0)0.6±0.7 (0.0–2.3)2.1±3.7 (0.0–18.0)2.0±3.4 (0.0–10.0)7.1±6.4 (0.6–14.0)
 Eosinophils %0.7±2.3 (0.0–17.0)0.3±0.4 (0.0–1.3)1.0±3.0 (0.0–17.0)0.2±0.4 (0.0–1.0)1.8±2.8 (0.0–5.0)
 CD3+ %86.1±11.8 (36.0–98.0)91.1±4.9# (79.0–97.0)85.1±11.4 (51.0–98.0)87.4±9.7 (67.0–96.0)72.5±25.0 (36.0–92.0)
 CD4+ %67.8±17.9 (23.0–92.0)78.7±9.4# (54.0–92.0)64.7±18.5 (23.0–87.0)66.6±19.6 (33.0–90.0)52.5±19.7 (30.0–74.0)
 CD8+ %16.5±13.4 (2.0–74.0)11.8±8.9# (2.0–42.0)18.8±16.0 (4.0–74.0)18.5±10.5 (4.7–36.0)11.5±4.4 (8.0–18.0)
 CD19+ %0.6±1.0 (0.0–6.0)0.6±1.1# (0.0–4.0)0.6±1.1 (0.0–6.0)0.5±0.7 (0.0–2.0)0.5±1.0 (0.0–2.0)
 BAL fluid CD4+/CD8+ ratio7.6±7.3 (0.3–46.0)10.3±10.0# (1.3–46.0)6.8±6.0 (0.3–21.3)6.8±7.3 (1.3–19.1)5.0±2.3 (2.4–7.4)
  • Data are presented as n or mean±sd (range). CXR: chest radiograph; LS: Löfgren's syndrome; BAL: bronchoalveolar lavage. #: T-cell population data were not available for one subject.